Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients

Yong Luo, Qiankun Li, Xiaobing Yang, Dechao Wei, Bingfu Feng, Mingchuan Li, Yili Han, Jiahui Zhao, Yunhua Lin, Qing Li, Zhu Hou, Hong-Yu Zhuang, Yongguang JiangDisease 2021 · DOI

TL;DR

This study identifies the overexpression of CXCR7 as a significant indicator of resistance to enzalutamide (Enza), a key treatment for castration-resistant prostate cancer (CRPC). The findings suggest that CXCR7 could serve as a novel biomarker for predicting treatment response and a potential therapeutic target to overcome Enza resistance in CRPC patients.

What Problem Does This Paper Address?

Prostate cancer (PCa) progression is heavily influenced by the androgen receptor (AR) signaling pathway. While androgen deprivation therapy (ADT) is a standard treatment, most patients eventually develop resistance, progressing to metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide (Enza) is a second-generation AR antagonist that has shown efficacy, but a significant portion of patients either don't respond or develop resistance to it. This resistance is a major clinical challenge, highlighting the need to understand the underlying molecular mechanisms and identify predictive biomarkers. Previous research by the authors suggested a link between CXCR7 derepression and Enza resistance, proposing that CXCR7 might activate AR-independent pathways driving CRPC progression. This paper aims to further validate this hypothesis by investigating the correlation between CXCR7 expression levels in CRPC patients and their response to Enza treatment, as well as their clinical outcomes.

Methods

The study employed immunohistochemical (IHC) staining to assess CXCR7 expression in prostatic biopsy tissues from CRPC patients. Patients were categorized into CXCR7-negative and CXCR7-positive groups, with the latter further stratified based on the intensity and extent of CXCR7 staining (1+, 2+, 3+). The primary outcome measures were prostate-specific antigen (PSA) progression-free survival (PSAP-FS) and clinical or radiographic progression-free survival (CRP-FS). Statistical analyses included Cox proportional hazards modeling and Kaplan-Meier analysis to evaluate the relationship between CXCR7 expression and treatment outcomes. Patient characteristics were compared using chi-square tests or Kruskal-Wallis tests.

Datasets

The study utilized data from 79 CRPC patients treated at Beijing Anzhen Hospital between January 2015 and December 2019. These patients had undergone radical prostatectomy, docetaxel-based chemotherapy, or new endocrine therapies, including Enza or abiraterone. The dataset included clinicopathological features and follow-up data on PSA levels and clinical/radiographic progression. No new benchmarks were introduced; the study focused on analyzing existing patient data.

Key Insights and Ideas

  • CXCR7 as a resistance marker: The most striking insight is the strong correlation between higher CXCR7 expression and resistance to enzalutamide. This suggests CXCR7 is not just a bystander but an active player in the development of resistance.
  • AR-independent signaling: The findings support the idea that CXCR7 may mediate AR-independent signaling pathways, which are crucial for tumor progression when AR signaling is blocked by Enza. This opens up new avenues for therapeutic strategies that bypass AR.
  • Graded response to CXCR7 levels: The study demonstrates a dose-dependent relationship between CXCR7 expression and resistance. Higher levels of CXCR7 (3+ vs. 2+ vs. 1+) are associated with progressively worse outcomes, providing a nuanced understanding of its role.
  • Potential therapeutic target: The authors propose CXCR7 as a novel therapeutic target, suggesting that inhibiting CXCR7 could potentially re-sensitize tumors to Enza or improve treatment outcomes independently.

Key Results

  • PSA Response: Patients with lower CXCR7 expression showed significantly better PSA response to Enza. 84.4% of CXCR7-negative patients had decreasing PSA compared to 71.4% in the CXCR7/1+ group, 31.2% in the CXCR7/2+ group, and 0% in the CXCR7/3+ group. Notably, 68.8% of CXCR7-negative patients achieved a >50% PSA decrease, compared to only 8.5% of CXCR7-positive patients (P < 0.001).
  • PSA Progression-Free Survival (PSAP-FS): CXCR7-negative patients had significantly longer median PSAP-FS (21 months) compared to CXCR7-positive patients (6 months, P < 0.0001). Stratified analysis of CXCR7-positive patients showed that higher expression levels correlated with shorter PSAP-FS (21 months for 1+, 9 months for 2+, and 6 months for 3+).
  • Clinical/Radiographic Progression-Free Survival (CRP-FS): Similarly, CXCR7-negative patients exhibited significantly improved median CRP-FS (27 months) compared to CXCR7-positive patients (9 months, P < 0.0001). The stratified analysis also revealed a clear trend of shorter CRP-FS with increasing CXCR7 expression (21 months for 1+, 12 months for 2+, and 6 months for 3+).

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-center study design: This limits the generalizability of the findings.
  • Small cohort size: A larger, multi-center study is needed to confirm the predictive value of CXCR7.
  • Detection of CXCR7: The reliance on prostatic biopsy samples limits its application in patients who have undergone radical prostatectomy. While circulating tumor cells (CTCs) are mentioned as a potential alternative, the detection rate was too low in this study, indicating a technical challenge for measuring CXCR7 derepression in blood samples.

Future work should focus on:

  • Validating CXCR7 as a biomarker in larger, diverse patient cohorts.
  • Investigating the precise molecular mechanisms by which CXCR7 confers Enza resistance, particularly its role in AR-independent signaling.
  • Developing and testing CXCR7-targeting therapies, either as monotherapy or in combination with Enza, to overcome resistance and improve patient outcomes.
  • Exploring more effective methods for detecting CXCR7 expression in accessible samples, such as blood, to facilitate its clinical application.

Summary updated

Abstract

Overexpression of CXCR7 induced by an AR antagonist in CRPC patients displays much better treatment response to Enza. CXCR7 might be a novel therapeutic target gene for CRPC patients.
BibTeX
@inproceedings{luo2021overexpression,
  author = {Yong Luo and Qiankun Li and Xiaobing Yang and Dechao Wei and Bingfu Feng and Mingchuan Li and Yili Han and Jiahui Zhao and Yunhua Lin and Qing Li and Zhu Hou and Hong-Yu Zhuang and Yongguang Jiang},
  title = {{Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients}},
  booktitle = {Disease},
  year = {2021},
  doi = {10.1155/2021/6649579},
}
Figure